LGHT Langar Global HealthTech ETF
ETF on NYSE (US) · Actively managed · Listing
Most notable sale · Intuitive Surgical, Inc.
Intuitive Surgical, Inc. cut by 37%
Shares went from 985 to 617 ($454K → $245K). Now 9.9% of the portfolio. Estimated trade $146K.
Most notable buy · Moderna, Inc.
Moderna, Inc. raised by 29%
Shares went from 2,177 to 2,819 ($111K → $197K). Now 8.0% of the portfolio. Estimated trade $45.0K.
Largest holding: UMB MONEY MARKET, raised 5.6x, 416,342 units ($416K).
| Current positions Top 10 | % of book |
|---|---|
| UMB MONEY MARKET AMBXX $416K · 5.6x units | 16.8% |
| Intuitive Surgical, Inc. ISRG $245K · −37% sh | 9.9% |
| ResMed Inc. RMD $225K · −15% sh | 9.1% |
| Moderna, Inc. MRNA $197K · +29% sh | 8.0% |
| Veeva Systems Inc. VEEV $138K · −29% sh | 5.6% |
| GE HealthCare Technologies Inc. GEHC $134K · −45% sh | 5.4% |
| IQVIA Holdings, Inc. IQV $123K · −31% sh | 5.0% |
| Koninklijke Philips N.V. NY Registry Shares PHG $114K · −29% sh | 4.6% |
| Insulet Corporation PODD $110K · −13% sh | 4.4% |
| DexCom, Inc. DXCM $99.2K · −31% sh | 4.0% |
Slices are % of holdings value. Changes ("sh" shares, "units" other holdings) are in the quantity held against Mar 31, 2026.
| Sectors | % of holdings value |
|---|---|
| Healthcare | 70.1% |
| Technology | 5.6% |
| Communication Services | 1.6% |
| Unclassified | 22.7% |
| Industries | % of holdings value |
|---|---|
| Medical Devices | 47.7% |
| Biotechnology | 12.5% |
| Software - Application | 5.6% |
| Health Information Services | 5.1% |
| Healthcare Plans | 4.5% |
| Internet Content & Information | 1.6% |
| Medical Care Facilities | 0.3% |
| Unclassified | 22.7% |
| Initiations 0 | Value |
|---|---|
| None this period. | |
| Increases 7 | Change |
|---|---|
| Moderna, Inc. MRNA $111K → $197K | +29% |
| iRhythm Holdings, Inc. IRTC $33.9K → $59.1K | +73% |
| Alignment Healthcare, Inc. ALHC $16.5K → $46.4K | 2.1x |
| Doximity, Inc. DOCS $38.5K → $40.1K | +17% |
| Privia Health Group, Inc. PRVA $30.4K → $40.3K | +6% |
| PROCEPT BioRobotics Corporation PRCT $14.2K → $14.5K | +13% |
| Phreesia, Inc. PHR $2.88K → $3.65K | +3% |
| Reductions 21 | Change |
|---|---|
| Intuitive Surgical, Inc. ISRG $454K → $245K | −37% |
| GE HealthCare Technologies Inc. GEHC $272K → $134K | −45% |
| Siemens Healthineers $155K → $78.8K | −45% |
| Veeva Systems Inc. VEEV $194K → $138K | −29% |
| IQVIA Holdings, Inc. IQV $158K → $123K | −31% |
| Zimmer Biomet Holdings, Inc. ZBH $151K → $92.8K | −36% |
| BioNTech SE BNTX $114K → $71.4K | −40% |
| Koninklijke Philips N.V. NY Registry Shares PHG $163K → $114K | −29% |
| DexCom, Inc. DXCM $134K → $99.2K | −31% |
| Sonova Holding AG $104K → $64.6K | −40% |
| ResMed Inc. RMD $307K → $225K | −15% |
| Alkermes plc ALKS $41.5K → $35.1K | −43% |
| Terminations 2 | Change |
|---|---|
| Masimo Corp was $86.1K | −100% |
| Cochlear Ltd was $55.6K | −100% |
The other 9 reductions
Align Technology, Inc. (−24%), Insulet Corporation (−13%), Omnicell, Inc. (−28%), Teladoc Health, Inc. (−31%), LifeStance Health Group, Inc. (−27%), Progyny, Inc. (−12%), Schrodinger, Inc. (−25%), Tandem Diabetes Care, Inc. (−9%), TRUEBRIDGE INC (−20%)
Source: the fund's quarterly portfolio reports to the SEC, the portfolio of Jun 30, 2026 (Form N-PORT) vs the portfolio of Mar 31, 2026 (Form N-PORT). Percent changes are changes in the quantity held (shares, or units for holdings that are not a listed equity); dollar values are as reported at each period end. Each column is ranked by the estimated dollar size of the trade: a new or closed position at its value, otherwise the change in shares at the position's own period-end price. Where shares and price per share moved by inverse whole multiples (a split), the earlier share count is restated. Cash and money-market lines are in the book and its value but are never counted as trades. Short positions are listed as such, at their (negative) printed value.
Objective
From the summary prospectus filed May 6, 2026.
Langar Global HealthTech ETF (the "Fund") seeks long-term growth of capital.
Principal investment strategies
As an actively managed exchange-traded fund ("ETF"), the Fund will not seek to replicate the performance of an index. The Fund intends to achieve its investment objective by investing a majority of its net assets in U.S. and foreign exchange-listed healthcare technology companies in the U.S. and a number of developed countries around the world. Under normal circumstances, the Fund will invest at least 80% of the Fund's net assets (plus borrowings for investment purposes) in U.S. and foreign exchange-listed equity securities of healthcare technology companies and American Depository Receipts ("ADRs") on those securities. These securities may be of any market capitalization. 2 Langar Investment Management, LLC (the "Advisor") uses a combination of a top-down review and a bottom-up research methodology to select fundamentally strong companies that develop technology to create efficiency in healthcare by addressing key pain points for patients, providers, payors, and/or hospitals. The Advisor defines pain points as consistent problems that a patient, provider and/or other healthcare stakeholder has when dealing with a product and/or service, which are unmet needs that are not adequately addressed for a company to solve in the market. These companies are generally in one of the nine subsectors described below and may include robotic surgery companies, virtual and/or telemedicine companies, companies that develop next-generation insurance payment models, drug development companies leveraging artificial intelligence (AI), digital clinical trial companies, companies that address operational issues within a hospital, and companies that leverage large language model (LLM) AI to develop next best recommendation engines to improve/facilitate the intake, monitoring, and treatment of a patient. The Advisor's selection process has four main steps (as further described below): 1) Langar's HealthTech classification; 2) Langar Rating™; 3) Langar's HealthTech Industry Risk Score; and 4) Investment Committee review. Langar's HealthTech Classification The Advisor starts by recategorizing public companies in the healthcare industry as defined by the Standard & Poor's Global Industry Classification Standard ("GICS") to determine the companies that fit into the Advisor's definition of a HealthTech company. The Advisor defines a "HealthTech Company" as a company that: i) develops technology to create efficiencies in healthcare by addressing key pain points of patients, providers, payors and/or hospitals; and ii) receives a majority of its revenue from HealthTech products and/or services as reported through filings with the SEC. HealthTech companies can be grouped into nine subsectors: Public HealthTech subsector definitions: • Access to Care – Provide care outside of a hospital setting through virtual, in-person, or a hybrid care combination. • Biopharma – Pharmaceutical and biotechnology companies that use artificial intelligence/machine learning ("AI/ML") technologies as an integral part of their drug design or development process. • Clinical Trials – Enables the efficient deployment, tracking and/or completion of trials that support novel medications and/or treatments. • Decision Support – Provides clinicians with patient-specific information, which is intelligently filtered or presented at appropriate times to enhance care. • Hospital Operations – Improves the efficiency of hospital workflows that are required to provide care. • Insurance – Leverage AI/ML models to save costs and improve services of private and/or government programs. • Treatment Device – Devices that leverage an AI/ML algorithm to facilitate treatment of a specific medical problem. Private HealthTech subsector definitions: • Lifestyle Wellness – Assists users in navigating their overall health and wellness journey using monitoring, counseling, education, and lifestyle changes that help prevent, treat, and provide care.
Management and Contact
- Adviser
- Langar Investment Management, LLC
- Portfolio managers
-
Dhruv K. Vig, Ph.
D., is the portfolio manager of the Fund and is primarily responsible for the day-to-day management of the Fund's portfolio.
Dr. Vig has served as the Fund's portfolio manager since its inception in January 2024.
- Phone
- 1-800-773-3863
- [email protected]
- Website
- langarfunds.com
Track Record as of Dec 31, 2025
Average annual total returns from the summary prospectus. Returns in percent; periods over a year are annualized.
| 1 Year | Since Inception | |
|---|---|---|
| S&P 500 Health Care Index (reflects no deductions for fees and expenses) | 14.60% | 6.91% |
| S&P 500 Index (reflects no deductions for fees and expenses) | 17.88% | 21.81% |
Holdings as of Jun 30, 2026
The full portfolio as of the quarter end Jun 30, 2026, from the fund's report to the SEC (Form N-PORT, filed Aug 28, 2026), the newest we have: we do not read a daily file from this fund's website, or the filing is newer. Every line is listed: holdings we could identify link to their page, the rest (bonds, CLOs, loans, derivatives, securities we do not carry) are shown as filed, debt with its coupon and maturity; Shares is the principal amount for debt. Short positions are negative. Change is the share count against the filing of Mar 31, 2026.
29 lines, 25 linked, weights sum to 100.02% · Actively managed (N-CEN)
| Holding | Ticker / identifier | Type | Shares | Change | Weight | Market value |
|---|---|---|---|---|---|---|
|
UMB MONEY MARKET
|
AMBXX | Money market | 416,341.6 | +342,331.4 | 16.83% | $ 416.342K |
| Intuitive Surgical I | US46120E6023 | Equity | 617 | −368 | 9.92% | $ 245.369K |
| ResMed Inc | US7611521078 | Equity | 1,156 | −210 | 9.11% | $ 225.281K |
| Moderna Inc | US60770K1079 | Equity | 2,819 | +642 | 7.98% | $ 197.415K |
| Veeva Systems Inc | US9224751084 | Equity | 780 | −322 | 5.60% | $ 138.427K |
| GE HealthCare | US36266G1076 | Equity | 2,091 | −1,734 | 5.41% | $ 133.845K |
| IQVIA Holdings Inc | US46266C1053 | Equity | 638 | −287 | 4.98% | $ 123.274K |
| Koninklijke Philips | US5004723038 | Equity | 4,202 | −1,755 | 4.62% | $ 114.252K |
| Insulet Corp | US45784P1012 | Equity | 721 | −109 | 4.44% | $ 109.772K |
| DEXCOM INC COM | US2521311074 | Equity | 1,473 | −668 | 4.01% | $ 99.207K |
| Zimmer Biomet Holdin | US98956P1021 | Equity | 1,078 | −594 | 3.75% | $ 92.805K |
|
Siemens Healthineers
|
US82622J1043 | Equity | 4,048 | −3,268 | 3.19% | $ 78.815K |
| BioNTech SE | US09075V1026 | Equity | 767 | −515 | 2.88% | $ 71.369K |
| Align Technology Inc | US0162551016 | Equity | 399 | −125 | 2.72% | $ 67.295K |
|
Sonova Holding AG
|
US83569C1027 | Equity | 1,365 | −925 | 2.61% | $ 64.578K |
| iRhythm Holdings | US4500561067 | Equity | 497 | +210 | 2.39% | $ 59.118K |
| Alignment Healthcare | US01625V1044 | Equity | 1,950 | +1,011 | 1.88% | $ 46.43K |
| Privia Health Group | US74276R1023 | Equity | 1,568 | +88 | 1.63% | $ 40.345K |
| Doximity Inc | US26622P1075 | Equity | 1,934 | +281 | 1.62% | $ 40.111K |
| Alkermes PLC | IE00B56GVS15 | Equity | 670 | −505 | 1.42% | $ 35.105K |
| Progyny Inc | US74340E1038 | Equity | 551 | −74 | 0.64% | $ 15.885K |
| PROCEPT BioRobotics | US74276L1052 | Equity | 641 | +73 | 0.59% | $ 14.474K |
| Omnicell Inc | US68213N1090 | Equity | 271 | −105 | 0.45% | $ 11.252K |
| Teladoc Inc | US87918A1051 | Equity | 1,052 | −467 | 0.36% | $ 8,920.96 |
| LifeStance Health Gr | US53228F1012 | Equity | 645 | −237 | 0.28% | $ 6,907.95 |
| Tandem Diabetes Care | US8753722037 | Equity | 437 | −42 | 0.27% | $ 6,594.33 |
| SCHRODINGER INC | US80810D1037 | Equity | 382 | −127 | 0.25% | $ 6,207.50 |
| PHREESIA INC | US71944F1066 | Equity | 355 | +11 | 0.15% | $ 3,652.95 |
|
TRUEBRIDGE INC
|
US2053061030 | Equity | 40 | −10 | 0.04% | $ 1,048.40 |
Trades Mar 31, 2026 to Jun 30, 2026
Changes in shares between the fund's two newest published portfolios, cash left out. Value is the change at the line's own price in the newer portfolio.
| Holding | Ticker | Action | Before | After | Change | Value |
|---|---|---|---|---|---|---|
| Intuitive Surgical I | Sold | 985 | 617 | −368 | $ -146.346K | |
| GE HealthCare | Sold | 3,825 | 2,091 | −1,734 | $ -110.993K | |
|
Masimo Corp
|
Closed | 484 | — | −484 | $ -86.089K | |
|
Siemens Healthineers
|
Sold | 7,316 | 4,048 | −3,268 | $ -63.628K | |
| Veeva Systems Inc | Sold | 1,102 | 780 | −322 | $ -57.145K | |
|
Cochlear Ltd
|
Closed | 943 | — | −943 | $ -55.637K | |
| IQVIA Holdings Inc | Sold | 925 | 638 | −287 | $ -55.454K | |
| Zimmer Biomet Holdin | Sold | 1,672 | 1,078 | −594 | $ -51.137K | |
| BioNTech SE | Sold | 1,282 | 767 | −515 | $ -47.921K | |
| Koninklijke Philips | Sold | 5,957 | 4,202 | −1,755 | $ -47.718K | |
| DEXCOM INC COM | Sold | 2,141 | 1,473 | −668 | $ -44.99K | |
| Moderna Inc | Bought | 2,177 | 2,819 | +642 | $ 44.959K | |
|
Sonova Holding AG
|
Sold | 2,290 | 1,365 | −925 | $ -43.762K | |
| ResMed Inc | Sold | 1,366 | 1,156 | −210 | $ -40.925K | |
| Alkermes PLC | Sold | 1,175 | 670 | −505 | $ -26.459K | |
| iRhythm Holdings | Bought | 287 | 497 | +210 | $ 24.98K | |
| Alignment Healthcare | Bought | 939 | 1,950 | +1,011 | $ 24.072K | |
| Align Technology Inc | Sold | 524 | 399 | −125 | $ -21.083K | |
| Insulet Corp | Sold | 830 | 721 | −109 | $ -16.595K | |
| Doximity Inc | Bought | 1,653 | 1,934 | +281 | $ 5,827.94 | |
| Omnicell Inc | Sold | 376 | 271 | −105 | $ -4,359.60 | |
| Teladoc Inc | Sold | 1,519 | 1,052 | −467 | $ -3,960.16 | |
| LifeStance Health Gr | Sold | 882 | 645 | −237 | $ -2,538.27 | |
| Privia Health Group | Bought | 1,480 | 1,568 | +88 | $ 2,264.24 | |
| Progyny Inc | Sold | 625 | 551 | −74 | $ -2,133.42 | |
| SCHRODINGER INC | Sold | 509 | 382 | −127 | $ -2,063.75 | |
| PROCEPT BioRobotics | Bought | 568 | 641 | +73 | $ 1,648.34 | |
| Tandem Diabetes Care | Sold | 479 | 437 | −42 | $ -633.78 | |
|
TRUEBRIDGE INC
|
Sold | 50 | 40 | −10 | $ -262.10 | |
| PHREESIA INC | Bought | 344 | 355 | +11 | $ 113.19 |
Podcast Mentions
Sign up to see podcast mentions and sentiment
Sign Up